| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC5183 | I-BET151 Featured | I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively. |
|
| DC9658 | I-BRD9 Featured | I-BRD9 is a potent and selective BRD9 inhibitor (pIC50 = 7.3). Exhibits >70-fold selectivity for BRD9 over a panel of 34 other bromodomains and >700-fold selectivity over the BET family. |
|
| DC9982 | I-CBP112 Featured | I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC50 = 0.142 and 0.625 μM, respectively). |
|
| DC7487 | Pyroxamide Featured | Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells. |
|
| DC7614 | IOX1 Featured | IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. |
|
| DC10220 | ITSA-1 (ITSA1) Featured | ITSA-1 (ITSA1) is an HDAC activator via TSA suppression, but shows no activity towards other HDAC inhibitors. |
|
| DC11421 | JQEZ5 Featured | JQEZ5 is a novel and potent EZH2 inhibitor. |
|
| DC10586 | KDM4D-IN-1 Featured | KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC50 value of 0.41±0.03 μM. |
|
| DC10285 | KDM5-IN-1 Featured | KDM5-IN-1 is a potent, selective and orally bioavailable KDM5 inhibitor with an IC50 of 15.1 nM. |
|
| DC8578 | L002(NSC764414) Featured | L002 is a p300 inhibitor (IC50=1.98 μM) that inhibits p53 and histone acetylation. Suppresses STAT3 activation in vitro and suppresses tumor growth in some mouse cell lines. |
|
| DC7856 | LLY-507 Featured | LLY-507 is a chemical probe for SMYD2 (a protein lysine methyltransferase). |
|
| DC4241 | LMK-235 Featured | LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor (IC50 values are 4.22, 11.9, 55.7, 320, 852, 881, and 1278 nM for HDAC 5, 4, 6, 1, 11, 2, and 8, respectively). |
|
| DC8541 | ORY-1001(Ladademstat) Featured | ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
|
| DC11106 | Vafidemstat (ORY-2001) Featured | Vafidemstat (ORY-2001) is an oral, brain penetrant drug that inhibits LSD1 and MAOB by reducing cognitive impairment, including memory loss and neuroinflammation. It also has neuroprotective effects. |
|
| DC10560 | MAK683 Featured | MAK683 is a novel PRC2/EED inhibitor. |
|
| DC5128 | MC1568 Featured | MC1568 is a class II (IIa) HDAC inhibitor selective for HDAC4 and HDAC6 |
|
| DC10940 | MC3343 Featured | MC3343 (MC-3343) is a novel potent, non-nucleoside DNA methyltransferase (DNMT) inhibitor with IC50 of 5.7 and 1.7 uM for DNMT1 and DNMT3a. |
|
| DC7794 | MG149 Featured | MG 149 is an inhibitor of histone acetyltransferases (HAT) with IC50 values of 74μM and 47μM for Tip60 and MOF, respectively. |
|
| DC7196 | MGCD0103 (Mocetinostat) Featured | MGCD0103 (Mocetinostat) is a potent HDAC inhibitor with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3, respectively. |
|
| DC8546 | MI-136 Featured | MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes. |
|
| DC8544 | MI-463 Featured | MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction. |
|
| DC8545 | MI-503 Featured | MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-MLL interaction. |
|
| DC10287 | MI-538 Featured | MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC50 of 21 nM. |
|
| DC11045 | miR-21 inhibitor 37 | miR-21 inhibitor 37 is a novel inhibitor of miR-21 function with EC50 of 5.3 uM in HeLa-miR21-Luc assays, displays no inhibition of miR-122. |
|
| DC9836 | Mivebresib(ABBV-075） Featured | Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. |
|
| DC7740 | ML-324 Featured | ML-324 is a JMJD2 histone demethylase inhibitor (JMJD2 IC50 = 920 nM) |
|
| DC7562 | MM-102 Featured | MM-102 is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM. |
|
| DC10063 | MPI-5a Featured | MPI_5a is a potent selective inhibitor of HDAC6, and poorly blocks other HDAC enzymes. |
|
| DC10951 | MPT0E028 | MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA. |
|
| DC10938 | MPT0G211 | MPT0G211 is a novel potent, selective HDAC6 inhibitor with IC50 of 0.291 nM, displays >1,000-fold selectivity over other HDAC isoforms. |
|
